Bangalore-based contract researcher Syngene International said its ongoing drug research and development collaboration with US biotech giant Amgen Inc has been extended till 2026. The collaborative programme to address some of the most serious diseases in the world was started in 2012 and Syngene had established a dedicated R&D center– Syngene Amgen Research and Development Center in 2016 — to conduct drug discovery and development projects as part of Amgen’s global R&D program. With the extension, the Indian company will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen research and development projects.